Eli Lilly and Company (LLY) stock news
The latest Eli Lilly and Company news and press releases. 2 news stories in the last 24 hours, 1.5 times its usual daily coverage. LLY stock report · Market news
Latest news
- $1,000 Invested in Eli Lilly 10 Years Ago Would Be Worth a Fortune Today 24/7 Wall Street, Nov 19, 6:17 PM UTC
One molecule turned a diversified drugmaker into a trillion-dollar giant, yet recent buyers have watched shares swing hard even as revenue surged. Does Lilly's next chapter justify today's price, or has the best part ... - Is Immunology Emerging as Eli Lilly's Next Growth Driver? Zacks Investment Research, Nov 19, 3:25 PM UTC
Lilly is expanding its immunology franchise through growing drug sales, promising pipeline candidates and strategic acquisitions. - Eli Lilly: Everyone Losing Weight, But Lilly Keeps Gaining (Initiating With A Buy) Seeking Alpha, Nov 19, 9:11 AM UTC
Eli Lilly and Company earns a buy rating and a $1,600 target as volume growth outweighs pricing pressure and the pipeline advances. Q3 volume rose 53% despite 15% lower realized prices; management raised 2026 revenue ... - Weight-loss drugs' hit to UK grocery spending tops £1 billion, Worldpanel says Reuters, Nov 19, 12:03 AM UTC
The impact of weight-loss drugs on UK grocery spending has surpassed £1 billion ($1.32 billion), as new pill formats and rising uptake among men accelerate their use, researcher Worldpanel by Numerator said on Thurs... - Worried investors are paying up for these stocks — some with up to 49% upside, analysts say Market Watch, Nov 18, 4:04 PM UTC
Defensive sectors have beaten the S&P 500 by a wide margin in recent months, even though they are priced much higher relative to earnings estimates than the index. - Eli Lilly Caught in Vendor Hack as Extortion Group Threatens to Leak Data on 1.2 Million Patients Barrons, Nov 17, 4:05 PM UTC
Lilly found no unauthorized access to its own systems, a person familiar with the matter said. Extortion group n0n claims to hold patient and prescriber data. - Lilly Bets Up to $1.5 Billion on Calytrix's Preclinical Antibody GuruFocus, Nov 16, 5:55 PM UTC
Eli Lilly and Co. (LLY) agreed to acquire Calytrix Bio for up to $1.5 billion in cash. The total includes an upfront payment and further payments tied to clinic - Eli Lilly to Buy Calytrix Bio for Up to $1.5 Billion WSJ, Nov 16, 4:58 PM UTC
Calytrix Bio, a privately held biotechnology company backed by JPMorgan Chase, is developing therapies aimed at a group of rare blood cancers. - Prediction: $10,000 Equally Split Between Eli Lilly and Novo Nordisk Will Be Worth This Much by the End of 2027 The Motley Fool, Nov 15, 11:30 PM UTC
Eli Lilly is surging, with revenue up 39% in the third quarter and a retatrutide filing planned for early 2027. Novo is bouncing back on oral Wegovy, with a CagriSema decision due soon. - 2,565 Shares in Eli Lilly and Company $LLY Bought by California First Leasing Corp Defense World, Nov 15, 4:27 PM UTC
California First Leasing Corp bought a new stake in Eli Lilly and Company (NYSE: LLY) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. ... - Top 50 High-Quality Dividend Growth Stocks For November 2026 Seeking Alpha, Nov 14, 4:12 PM UTC
I track 50 high-quality dividend growth stocks to identify favorable entry points, prioritizing long-term total return alongside a growing dividend stream. Forty stocks offer estimated future returns of at least 10%; ... - Bernicke Wealth Management Ltd. Makes New $5 Million Investment in Eli Lilly and Company $LLY Defense World, Nov 14, 12:23 PM UTC
Bernicke Wealth Management Ltd. purchased a new position in shares of Eli Lilly and Company (NYSE: LLY) in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. Th... - HIMS Partners With Lilly to Offer FDA-Approved Weight-Loss Drugs Zacks Investment Research, Nov 13, 5:16 PM UTC
Hims & Hers unites with Lilly to offer FDA-approved weight-loss drugs, Zepbound and Foundayo, expanding patient access and strengthening its obesity care platform. - 4 Key Stocks to Watch Across Diabetes and Obesity This Awareness Day Zacks Investment Research, Nov 13, 3:16 PM UTC
LLY, NVO, VKTX and GPCR advance diabetes and obesity treatments, with promising drug candidates, expanding clinical studies and key pipeline milestones ahead. - Mapping the Market: Eli Lilly shares ready to rally again Reuters, Nov 13, 11:10 AM UTC
Mapping the Market: Eli Lilly shares ready to rally again - Nvidia CEO Jensen Huang Says AI's 'Most Profound Impact' Will Be in Life Sciences -- and Eli Lilly Is Already Building on It The Motley Fool, Nov 12, 6:16 PM UTC
AI could improve the drug discovery and development process. Eli Lilly has made an important move to benefit from this. - The Big 3: JNJ, LLY, AAPL Schwab Network, Nov 12, 6:00 PM UTC
Amid the broader tech sell-off following Nvidia (NVDA) CEO Jensen Huang's resignation, Dan Deming looks to healthcare and “anti-AI” plays for stability. He says he's following the momentum in stocks including Johnson ... - China approves Eli Lilly's weight loss pill orforglipron Reuters, Nov 12, 7:22 AM UTC
China approves Eli Lilly's weight loss pill orforglipron - Eli Lilly Just Raised Its 2026 Sales Forecast to as Much as $92 Billion. But Is Viking Therapeutics the Next Big Obesity Winner? The Motley Fool, Nov 11, 10:34 PM UTC
Eli Lilly is one of the undisputed leaders in the weight loss market, and its progress in this area is helping it deliver excellent financial results. However, Viking Therapeutics, a smaller company, is also looking t... - Johnson & Johnson vs. Eli Lilly: Which Healthcare Giant's Stock Is a Better Buy for 2027? The Motley Fool, Nov 11, 8:00 PM UTC
Johnson & Johnson maintains a massive healthcare presence across both innovative medicines and advanced medical technologies. Eli Lilly is currently defined by explosive growth in the metabolic health market, particul... - EXCLUSIVE: Lilly, Gilead Face Near-Term Drug Pricing Risks As Washington Turns Up Heat Benzinga, Nov 11, 2:56 PM UTC
The next wave of U.S. drug-price negotiations could put billions of dollars in pharmaceutical revenue under pressure, with Eli Lilly and Co (NYSE:LLY), Gilead Sciences, Inc. (NASDAQ:GILD) facing more immediate exposur... - Hims & Hers Drops 18% as Q3 Loss and Profit Outlook Cut Disappoint; Novo Nordisk Slides 2%, Eli Lilly Holds Steady 24/7 Wall Street, Nov 10, 6:52 PM UTC
A surprise quarterly loss and a weaker profit outlook are hitting Hims & Hers (NYSE:HIMS) hard. Hims & Hers stock was last at $18.77, down 18%. - Hims & Hers Celebrated Its Eli Lilly Deal, Then Lost a Quarter of Its Value in a Week 24/7 Wall Street, Nov 10, 6:03 PM UTC
Shares of Hims & Hers (NYSE:HIMS) traded at $18.76 at midday Tuesday. That is 18.22% lower on the session and 25.67% lower over the past week. - 10 Dividend Growth Stocks: November 2026 Seeking Alpha, Nov 10, 2:00 PM UTC
In this monthly series, I rank a selection of dividend growth stocks and present the top 10 for consideration. To rank stocks, I sort candidates by quality score. This month's top 10, led by AMAT, LRCX, LLY, and AVGO,... - Novo Up 4% in a Month: How Should Investors Approach the Stock Now? Zacks Investment Research, Nov 9, 2:55 PM UTC
NVO gains 4% in a month on strong Q3 Wegovy pill sales and raised guidance, but intensifying competition and pricing pressures cloud its growth outlook. - 3 Large-Cap Stocks to Watch as Drug & Biotech Sector Rebounds in 2026 Zacks Investment Research, Nov 9, 2:45 PM UTC
In the Large-Cap Pharmaceuticals industry, LLY, NVS and BAYRY are worth watching as the industry shows a strong recovery. - Eli Lilly Is Much More Than a Weight-Loss Drug Company. Here's the Evidence The Motley Fool, Nov 7, 12:18 AM UTC
Some of Eli Lilly's products beyond its core therapeutic area are performing well. It also boasts a deep and diversified pipeline. - Telehealth Giant Hims & Hers Partners with Eli Lilly for Direct Weight Loss Drug Delivery Benzinga, Nov 6, 5:16 PM UTC
On Friday, Eli Lilly And Co. (NYSE:LLY) and Hims & Hers Health Inc. (NYSE:HIMS) announced a collaboration to broaden patient access to obesity medications Zepbound and Foundayo through the digital health platform. - Top Funds Feast On Shell, Microsoft, Palantir And 24 More Stocks Investors Business Daily, Nov 6, 1:00 PM UTC
The best mutual funds place massive bets on Microsoft, Palantir and Apple. But that's just the start. - 2 Defensive Healthcare Stocks Hitting New 52-Week Highs: ABBV & LLY Zacks Investment Research, Nov 6, 12:26 AM UTC
As tech stocks retreat, AbbVie (ABBV) and Eli Lilly (LLY) are hitting fresh 52-week highs, offering investors defensive healthcare exposure with compelling growth potential.
Press releases
- Lilly breaks ground in Pennsylvania's Lehigh Valley on a $3.5 billion site to make next-generation obesity medicines, the latest of 10 new U.S. sites since 2020 PRNewsWire, Nov 12, 8:30 PM UTC
Facility will manufacture injectable medicines, including retatrutide Site will create 850 high-wage jobs and 2,000 construction jobs INDIANAPOLIS, Nov. 12, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today... - New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy, patient-reported and metabolic outcomes at one year in adults with psoriatic arthritis and obesity PRNewsWire, Nov 11, 2:45 PM UTC
Nearly three times as many patients taking Taltz and Zepbound achieved ≥ 50% reduction in psoriatic arthritis disease activity (ACR50) at one year compared to Taltz alone in first-of-its-kind TOGETHER-PsA study Improv... - Life doesn't slow down, and Foundayo™ (orforglipron) patient Leanne Morgan is done waiting PRNewsWire, Nov 10, 1:00 PM UTC
After years of thinking she should be able to manage her weight on her own, Leanne shares how a conversation with her doctor led her to Foundayo, and why she encourages others to talk with their healthcare providers I... - Lilly's Foundayo (orforglipron) significantly reduced obstructive sleep apnea severity, reinforcing its potential to improve health beyond weight loss PRNewsWire, Nov 9, 2:30 PM UTC
In adults with moderate-to-severe OSA and obesity or overweight, Foundayo reduced breathing interruptions during sleep by up to an average of 44%, with up to 32% of participants achieving remission or mild disease Fo... - Lilly and Hims & Hers expand access to FDA-approved Lilly medicines PRNewsWire, Nov 6, 11:47 AM UTC
Agreement gives patients a path to FDA-approved treatments at self-pay price through the Hims & Hers platform INDIANAPOLIS, Nov. 6, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Hims & Hers Health, Inc. (... - Lilly to showcase new retatrutide, Taltz (ixekizumab) and Zepbound (tirzepatide) data at ACR Convergence 2026, advancing science at the intersection of rheumatologic conditions and obesity PRNewsWire, Nov 5, 11:45 AM UTC
Pivotal results from the Phase 3 TRIUMPH-1 and TRIUMPH-4 trials showed retatrutide delivered substantial reductions in knee pain and weight in adults with knee osteoarthritis and obesity, with some experiencing no kne... - Lilly reports third-quarter 2026 financial results, raises full-year guidance and highlights regulatory progress across the portfolio PRNewsWire, Oct 29, 10:45 AM UTC
Revenue in Q3 2026 increased 39% to $24.4 billion driven primarily by Mounjaro and Zepbound. Q3 revenue included approximately $900 million of benefits, primarily from $410 million of Jardiance milestones (no further ... - Lilly's retatrutide delivered greater A1C reduction and more than double the weight loss of Ozempic's highest approved dose in head-to-head trial PRNewsWire, Oct 28, 10:45 AM UTC
In adults with type 2 diabetes, retatrutide lowered A1C by an average of 2.2% vs. 1.8% with Ozempic 2 mg at 80 weeks Participants taking retatrutide lost an average of 44 lbs to 47 lbs (20% to 21%) vs. - Patrik Jonsson to retire after 36 years; Ilya Yuffa named president, Lilly Global Markets PRNewsWire, Oct 27, 8:03 PM UTC
Yuffa will take on an expanded role as the company scales for its next phase of growth Key highlights: Patrik Jonsson, executive vice president and president, Lilly International, has decided to retire at the end of ... - Lilly declares fourth-quarter 2026 dividend PRNewsWire, Oct 26, 3:19 PM UTC
INDIANAPOLIS, Oct. 26, 2026 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the fourth quarter of 2026 of $1.73 per share on outstanding common stock. The divide... - New data on Lilly's investigational treatment olomorasib at ESMO 2026 show durable first-line activity in KRAS G12C-mutant non-small cell lung cancer PRNewsWire, Oct 25, 7:30 AM UTC
Data presented at ESMO highlight the promising efficacy of olomorasib in combination with standard-of-care immunotherapy with or without chemotherapy in - Lilly presents first clinical data in platinum-sensitive ovarian cancer for its investigational, next-generation, FRα-targeting ADC at ESMO 2026 PRNewsWire, Oct 24, 6:30 AM UTC
Sofetabart mipitecan (Sofe-M) in combination with bevacizumab demonstrated a 79% confirmed objective response rate and 100% disease control rate, with similar activity observed across FR α expression levels Clinical a...
Headlines link to their publishers. Research data, not investment advice.